TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML

Cancer research · NSCLC

Efti (eftilagimod alpha) plus Keytruda (pembrolizumab) with chemotherapy achieved high response rates in the first-line treatment of patients with advanced or metastatic non‑squamous non‑small cell lung cancer (NSCLC), according to a news release from Immutep.

Efti (eftilagimod alpha) plus Keytruda (pembrolizumab) with chemotherapy achieved high response rates in the first-line treatment of patients with advanced or metastatic non‑squamous non‑small cell lung cancer (NSCLC), according to a news release from Immutep. Results were derived from the investigator‑initiated INSIGHT‑003 trial with a data‑cutoff date of May 6, 2025. Among all participants observed (51 patients), the overall response rate (ORR) was 60.8 % and the disease control rate (DCR) was 90.2 %. In patients with PD‑L1 tumor proportion scores (TPS) under 1 % (22 patients), the ORR was 54.5 % and the DCR was 86.4 %. Those with TPS between 1 % and 49 % (25 patients) had an ORR of 64 % and a DCR of 92 %. Patients with TPS under 50 % (47 patients) showed an ORR of 59.6 % and a DCR of 89.4 %. The highest rates were seen in the small subgroup with TPS of 50 % or higher (4 patients), with an ORR of 75 % and a DCR of 100 %.

These results suggest that the addition of the experimental immunotherapy Efti to standard checkpoint inhibition and chemotherapy may improve response rates in first‑line NSCLC patients, particularly those with low to intermediate PD‑L1 expression.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals